Literature DB >> 21712274

The European cardiac resynchronization therapy survey: patient selection and implantation practice vary according to centre volume.

Nigussie Bogale1, Silvia Priori, Anselm Gitt, Marco Alings, Cecilia Linde, Kenneth Dickstein.   

Abstract

AIMS: The European cardiac resynchronization therapy (CRT) survey is a joint initiative taken by the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology with the primary objective of describing current European practice associated with CRT implantations. The results demonstrated that a substantial number of implantations took place in patients without conventional guideline indications. We investigated whether the volume of implants per centre was a determinant of the propensity to use devices for 'off-label' indications. METHODS AND
RESULTS: One hundred and forty-one centres from 13 European countries contributed data from consecutive patients successfully implanted with a CRT-P or CRT-D device between November 2008 and June 2009. Centres were categorized into low volume (LVol; ≤ 120 implantations/year) and high volume (HVol; >120 implantations/year) based on median implantable cardioverter-defibrilator implantation the previous year. No differences were noted with regard to sex, age, or peri-procedural and device-related complications. High-volume centres implanted CRT devices in significantly more patients with mild symptoms and a narrow QRS width. The procedure and fluoroscopy times were substantially longer at LVol centres and devices were more frequently implanted by surgeons and interventional cardiologists. Patients stayed longer in hospital in LVol centres with a median of 4 (2-9) vs. 2 (2-6) days.
CONCLUSIONS: High-volume centres explore newer indications in their CRT practice and implant devices more frequently in patients with mild symptoms and narrow QRS durations. Electrophysiologists dominate implantation practice at HVol centres and duration of hospitalization is substantially shorter at these centres.

Entities:  

Mesh:

Year:  2011        PMID: 21712274     DOI: 10.1093/europace/eur173

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

1.  Better outcome at lower costs after implementing a CRT-care pathway: comprehensive evaluation of real-world data.

Authors:  Antonius M W van Stipdonk; Stijn Schretlen; Wim Dohmen; Christian Knackstedt; Fabienne Beckers-Wesche; Luuk Debie; Hans-Peter Brunner-La Rocca; Kevin Vernooy
Journal:  ESC Heart Fail       Date:  2022-05-31

2.  National Trends in the Use of Cardiac Resynchronization Therapy With or Without Implantable Cardioverter-Defibrillator.

Authors:  Charlotta Lindvall; Neal A Chatterjee; Yuchiao Chang; Betty Chernack; Vicki A Jackson; Jagmeet P Singh; Joshua P Metlay
Journal:  Circulation       Date:  2015-12-03       Impact factor: 29.690

3.  Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.

Authors:  Neal A Chatterjee; Rasmus Borgquist; Yuchiao Chang; Jennifer Lewey; Vicki A Jackson; Jagmeet P Singh; Joshua P Metlay; Charlotta Lindvall
Journal:  Eur Heart J       Date:  2017-05-14       Impact factor: 29.983

4.  EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors.

Authors:  Malek Khatib; José M Tolosana; Emilce Trucco; Roger Borràs; Angeles Castel; Antonio Berruezo; Adelina Doltra; Marta Sitges; Elena Arbelo; Maria Matas; Josep Brugada; Lluís Mont
Journal:  Eur J Heart Fail       Date:  2014-05-23       Impact factor: 15.534

5.  Cardiac resynchronization in Poland - comparable procedural routines? Insights from CRT Survey II.

Authors:  Mateusz Tajstra; Damian Łasocha; Elżbieta Gadula-Gacek; Mateusz Ostręga; Lidia Michalak; Dariusz Wojciechowski; Marek Zieliński; Maciej Kempa; Zbigniew Orski; Anna Polewczyk; Jerzy Ozga; Camilla Normand; Kenneth Dickstein; Cecilia Linde; Jarosław Kaźmierczak; Łukasz Szumowski; Mariusz Gąsior; Maciej Sterliński
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-12-08       Impact factor: 1.426

6.  Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.

Authors:  Eloi Marijon; Christophe Leclercq; Kumar Narayanan; Serge Boveda; Didier Klug; Jonathan Lacaze-Gadonneix; Pascal Defaye; Sophie Jacob; Olivier Piot; Jean-Claude Deharo; Marie-Cecile Perier; Genevieve Mulak; Jean-Sylvain Hermida; Paul Milliez; Daniel Gras; Olivier Cesari; Françoise Hidden-Lucet; Frederic Anselme; Philippe Chevalier; Philippe Maury; Nicolas Sadoul; Pierre Bordachar; Serge Cazeau; Michel Chauvin; Jean-Philippe Empana; Xavier Jouven; Jean-Claude Daubert; Jean-Yves Le Heuzey
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983

7.  Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy.

Authors:  Bogdan Beca; John L Sapp; Martin J Gardner; Christopher Gray; Amir AbdelWahab; Ciorsti MacIntyre; Steve Doucette; Ratika Parkash
Journal:  CJC Open       Date:  2019-03-06

8.  Development and implementation of a cardiac resynchronisation therapy care pathway: improved process and reduced resource use.

Authors:  Antonius Martinus Wilhelmus van Stipdonk; Stijn Schretlen; Wim Dohmen; Hans-Peter Brunner-LaRocca; Christian Knackstedt; Kevin Vernooy
Journal:  BMJ Open Qual       Date:  2021-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.